Ads
related to: newest drugs for lung cancer- How This Treatment Works
Explore Important Treatment Info
On The Official Patient Website.
- Learn About Treatment
Discover Why This aNSCLC Treatment
Option May Be Right For You.
- Patient Testimonials
Watch Videos & Hear From Real
Advanced NSCLC Patients.
- Patient Support Program
Sign Up For A Patient Support
Program For This aNSCLC Treatment.
- How This Treatment Works
Search results
Results from the WOW.Com Content Network
Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday.
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
Micrograph showing an ALK positive adenocarcinoma of the lung.The ALK immunostain allows individuals with ALK rearrangements to be identified.. ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1]
Lazertinib was approved for medical use in the United States in August 2024. [4]In November 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lazcluze, intended in combination with amivantamab, for the treatment of non-small cell lung cancer ...
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. [4] [5] It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. [7] [8] Sotorasib is an inhibitor of the RAS GTPase family. [4]
Ads
related to: newest drugs for lung cancer